Literature DB >> 28207070

Giardiasis Diagnosis and Treatment Practices Among Commercially Insured Persons in the United States.

Karlyn D Beer1, Sarah A Collier1, Fan Du2, Julia W Gargano3.   

Abstract

Background: Giardiasis, the most common enteric parasitic infection in the United States, causes an estimated 1.2 million episodes of illness annually. Published clinical recommendations include readily available Giardia-specific diagnostic testing and antiparasitic drugs. We investigated sequences of giardiasis diagnostic and treatment events using MarketScan, a large health insurance claims database.
Methods: We created a longitudinal cohort of 2995 persons diagnosed with giardiasis (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 007.1) from 2006 to 2010, and analyzed claims occurring 90 days before to 90 days after initial diagnosis. We evaluated differences in number and sequence of visits, diagnostic tests, and prescriptions by age group (children 1-17 years, adults 18-64 years) using χ2 tests and data visualization software.
Results: Among 2995 patients (212433 claims), 18% had a Giardia-specific test followed by or concurrent with an effective antiparasitic drug, without ineffective antibiotics. Almost two-thirds of patients had an antiparasitic and 27% had an antibiotic during the study window. Compared with children, adults more often had ≥3 visits before diagnosis (19% vs 15%; P = .02). Adults were also less likely to have a Giardia-specific diagnostic test (48% vs 58%; P < .001) and more likely to have an antibiotic prescription (28% vs 25%; P = .04). When Giardia-specific tests and antiparasitic and antibiotic prescriptions were examined, pediatric clinical event sequences most frequently began with a Giardia-specific test, whereas adult sequences most frequently began with an antiparasitic prescription. Conclusions: Giardiasis care infrequently follows all aspects of clinical recommendations. Multiple differences between pediatric and adult care, despite age-agnostic recommendations, suggest opportunities for provider education or tailored guidance. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  Giardia; MarketScan; administrative claims; data visualization

Mesh:

Substances:

Year:  2017        PMID: 28207070      PMCID: PMC5532738          DOI: 10.1093/cid/cix138

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

1.  Prevalence of enteric pathogens among community based asymptomatic individuals.

Authors:  M E Hellard; M I Sinclair; G G Hogg; C K Fairley
Journal:  J Gastroenterol Hepatol       Date:  2000-03       Impact factor: 4.029

2.  Temporal event sequence simplification.

Authors:  Megan Monroe; Rongjian Lan; Hanseung Lee; Catherine Plaisant; Ben Shneiderman
Journal:  IEEE Trans Vis Comput Graph       Date:  2013-12       Impact factor: 4.579

3.  Giardiasis in the United States - an epidemiologic and geospatial analysis of county-level drinking water and sanitation data, 1993-2010.

Authors:  Kerry Schnell; Sarah Collier; Gordana Derado; Jonathan Yoder; Julia Warner Gargano
Journal:  J Water Health       Date:  2016-04       Impact factor: 1.744

4.  Giardiasis surveillance -- United States, 2011-2012.

Authors:  Julia E Painter; Julia W Gargano; Sarah A Collier; Jonathan S Yoder
Journal:  MMWR Suppl       Date:  2015-05-01

5.  Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation.

Authors:  Bruce E Sands; Mei-Sheng Duh; Clorinda Cali; Anuli Ajene; Rhonda L Bohn; David Miller; J Alexander Cole; Suzanne F Cook; Alexander M Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-01       Impact factor: 2.890

6.  Administrative data used to identify patients with irritable bowel syndrome.

Authors:  Sarah L Goff; Andrew Feld; Susan E Andrade; Lisa Mahoney; Sarah J Beaton; Denise M Boudreau; Robert L Davis; Michael Goodman; Cynthia L Hartsfield; Richard Platt; Douglas Roblin; David Smith; Marianne Ulcickas Yood; Katherine Dodd; Jerry H Gurwitz
Journal:  J Clin Epidemiol       Date:  2008-03-04       Impact factor: 6.437

Review 7.  Extra-intestinal and long term consequences of Giardia duodenalis infections.

Authors:  Marie C M Halliez; André G Buret
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

8.  Incidence of acute gastroenteritis and role of norovirus, Georgia, USA, 2004-2005.

Authors:  Aron J Hall; Mariana Rosenthal; Nicole Gregoricus; Sharon A Greene; Jeana Ferguson; Olga L Henao; Jan Vinjé; Ben A Lopman; Umesh D Parashar; Marc-Alain Widdowson
Journal:  Emerg Infect Dis       Date:  2011-08       Impact factor: 6.883

9.  Irritable bowel syndrome and chronic fatigue 6 years after giardia infection: a controlled prospective cohort study.

Authors:  Kurt Hanevik; Knut-Arne Wensaas; Guri Rortveit; Geir Egil Eide; Kristine Mørch; Nina Langeland
Journal:  Clin Infect Dis       Date:  2014-08-12       Impact factor: 9.079

10.  Treatment of giardiasis after nonresponse to nitroimidazole.

Authors:  Eyal Meltzer; Tamar Lachish; Eli Schwartz
Journal:  Emerg Infect Dis       Date:  2014-10       Impact factor: 6.883

View more
  6 in total

1.  Are biopsies always necessary in upper and lower gastrointestinal endoscopy in children? A retrospective 10-year analysis.

Authors:  Rodrigo Corsato Scomparin; Pedro Luiz Toledo De Arruda Lourencao; Giovana Tuccile Comes; Wilson Elias De Oliveira Junior; Marcos Curcio Angelini; Paulo Cezar Haddad de Amorim; Simone Antunes Terra; Maria Aparecida Marchesan Rodrigues; Erika Veruska Paiva Ortolan
Journal:  Eur J Pediatr       Date:  2020-10-16       Impact factor: 3.183

2.  Response to Escobedo et al.

Authors:  Karlyn D Beer; Sarah A Collier; Fan Du; Julia W Gargano
Journal:  Clin Infect Dis       Date:  2018-07-18       Impact factor: 9.079

3.  Estimation of Direct Healthcare Costs of Fungal Diseases in the United States.

Authors:  Kaitlin Benedict; Brendan R Jackson; Tom Chiller; Karlyn D Beer
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

4.  Regulatory role of the intestinal microbiota in the immune response against Giardia.

Authors:  B Maertens; A Gagnaire; O Paerewijck; K De Bosscher; P Geldhof
Journal:  Sci Rep       Date:  2021-05-19       Impact factor: 4.379

Review 5.  Treatment-refractory giardiasis: challenges and solutions.

Authors:  Marco Lalle; Kurt Hanevik
Journal:  Infect Drug Resist       Date:  2018-10-24       Impact factor: 4.003

6.  Giardial lipid rafts share virulence factors with secreted vesicles and participate in parasitic infection in mice.

Authors:  Brian I Grajeda; Atasi De Chatterjee; Carmen M Villalobos; Breanna C Pence; Cameron C Ellis; Vanessa Enriquez; Sourav Roy; Sukla Roychowdhury; Aaron K Neumann; Igor C Almeida; Steven E Patterson; Siddhartha Das
Journal:  Front Cell Infect Microbiol       Date:  2022-08-23       Impact factor: 6.073

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.